{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:53:18Z","timestamp":1762001598446},"reference-count":26,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Relapse is a major problem after transplantation in children with acute B-lineage leukemias, and new therapies are needed to increase graft-versus-leukemia (GvL) effects without inducing graft-versus-host disease (GvHD). Here, we studied the ability of effector cells recovered from patients after transplantation with positive-selected stem cells from alternative donors to induce antibody-dependent cellular cytotoxicity (ADCC). For this purpose, a chimeric CD19 antibody, CD19-4G7chim, was generated. This antibody efficiently mediated ADCC against primary acute lymphoblastic leukemia (ALL) blasts by using purified natural killer (NK) cells from healthy donors or mononuclear cells from patients as effector cells. Increased lysis was obtained after stimulation of effector cells with interleukin-2 (IL-2). ADCC was not prevented by inhibitory effects mediated by HLA class I. We propose that treatment with chimeric CD19 antibodies leading to ADCC by donor-derived NK cells may become a therapeutic option for the post-transplantation treatment of minimal residual B-lineage ALLs.<\/jats:p>","DOI":"10.1182\/blood-2003-05-1735","type":"journal-article","created":{"date-parts":[[2004,2,10]],"date-time":"2004-02-10T01:23:35Z","timestamp":1076376215000},"page":"3982-3985","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell\u2013depleted allografts"],"prefix":"10.1182","volume":"103","author":[{"given":"Peter","family":"Lang","sequence":"first","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Barbin","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Greil","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J.","family":"Zunino","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Niethammer","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg H.","family":"Fey","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany; Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany; Stem Cell Transplantation Unit, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021218514349700_REF1","unstructured":"Aversa F, Terenzi A, Felicini R, et al. Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia. Bone Marrow Transplant. 1998;22(Suppl 5): S29-S32."},{"key":"2020021218514349700_REF2","doi-asserted-by":"crossref","unstructured":"Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27: 777-783.","DOI":"10.1038\/sj.bmt.1702996"},{"key":"2020021218514349700_REF3","doi-asserted-by":"crossref","unstructured":"Godder KT, Hazlett LJ, Abhyankar SH, et al. Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. J Clin Oncol. 2000;18: 1856-1866.","DOI":"10.1200\/JCO.2000.18.9.1856"},{"key":"2020021218514349700_REF4","doi-asserted-by":"crossref","unstructured":"Green A, Clarke E, Hunt L, et al. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. Blood. 1999;94: 2236-2246.","DOI":"10.1182\/blood.V94.7.2236.419k04_2236_2246"},{"key":"2020021218514349700_REF5","doi-asserted-by":"crossref","unstructured":"Lang P, Handgretinger R, Niethammer D, et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003;101: 1630-1636.","DOI":"10.1182\/blood-2002-04-1203"},{"key":"2020021218514349700_REF6","doi-asserted-by":"crossref","unstructured":"Ortin M, Raj R, Kinning E, Williams M, Darbyshire PJ. Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin. Bone Marrow Transplant. 2002;30: 359-366.","DOI":"10.1038\/sj.bmt.1703667"},{"key":"2020021218514349700_REF7","doi-asserted-by":"crossref","unstructured":"Bunin N, Carston M, Wall D, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood. 2002;99: 3151-3157.","DOI":"10.1182\/blood.V99.9.3151"},{"key":"2020021218514349700_REF8","doi-asserted-by":"crossref","unstructured":"Kook H, Goldman F, Padley D, et al. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood. 1996;88: 1089-1097.","DOI":"10.1182\/blood.V88.3.1089.1089"},{"key":"2020021218514349700_REF9","doi-asserted-by":"crossref","unstructured":"Lang P, Pfeiffer M, Handgretinger R, et al. Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. Bone Marrow Transplant. 2002;29: 497-502.","DOI":"10.1038\/sj.bmt.1703406"},{"key":"2020021218514349700_REF10","doi-asserted-by":"crossref","unstructured":"Reyburn H, Mandelboim O, Vales-Gomez M, et al. Human NK cells: their ligands, receptors and functions. Immunol Rev. 1997;155: 119-125.","DOI":"10.1111\/j.1600-065X.1997.tb00944.x"},{"key":"2020021218514349700_REF11","doi-asserted-by":"crossref","unstructured":"Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100: 1935-1947.","DOI":"10.1182\/blood-2002-02-0350"},{"key":"2020021218514349700_REF12","doi-asserted-by":"crossref","unstructured":"Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94: 333-339.","DOI":"10.1182\/blood.V94.1.333.413a31_333_339"},{"key":"2020021218514349700_REF13","unstructured":"Komatsu F, Tamiya H. Relationship between antibody-dependent cell-mediated cytotoxicity due to anti-HTLV-1 and negative signal of major histocompatibility complex class I antigens on adult T-cell leukemia cell lines. Oncol Res. 1998;10: 59-67."},{"key":"2020021218514349700_REF14","unstructured":"Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92: 1927-1932."},{"key":"2020021218514349700_REF15","doi-asserted-by":"crossref","unstructured":"Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98: 1326-1331.","DOI":"10.1182\/blood.V98.5.1326"},{"key":"2020021218514349700_REF16","doi-asserted-by":"crossref","unstructured":"Meeker TC, Miller RA, Link MP, et al. A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma. 1984;3: 305-320.","DOI":"10.1089\/hyb.1984.3.305"},{"key":"2020021218514349700_REF17","doi-asserted-by":"crossref","unstructured":"Krebber A, Bornhauser S, Burmester J, et al. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods. 1997;201: 35-55.","DOI":"10.1016\/S0022-1759(96)00208-6"},{"key":"2020021218514349700_REF18","unstructured":"Peipp M, Kupers H, Saul D, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002;62: 2848-2855."},{"key":"2020021218514349700_REF19","doi-asserted-by":"crossref","unstructured":"Liang M, Dubel S, Li D, et al. Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. J Immunol Methods. 2001;247: 119-130.","DOI":"10.1016\/S0022-1759(00)00322-7"},{"key":"2020021218514349700_REF20","doi-asserted-by":"crossref","unstructured":"Hauser TA, Malyguine AM, Dawson JR. Conformation dependence of MHC class I in the modulation of target cell sensitivity to natural killing. Hum Immunol. 1998;59: 71-76.","DOI":"10.1016\/S0198-8859(97)00243-7"},{"key":"2020021218514349700_REF21","unstructured":"Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol Res. 1998;10: 483-489."},{"key":"2020021218514349700_REF22","doi-asserted-by":"crossref","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63: 1424-1433.","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"2020021218514349700_REF23","doi-asserted-by":"crossref","unstructured":"Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994;84: 964-971.","DOI":"10.1182\/blood.V84.3.964.964"},{"key":"2020021218514349700_REF24","doi-asserted-by":"crossref","unstructured":"Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277: 26733-26740.","DOI":"10.1074\/jbc.M202069200"},{"key":"2020021218514349700_REF25","doi-asserted-by":"crossref","unstructured":"Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278: 3466-3473.","DOI":"10.1074\/jbc.M210665200"},{"key":"2020021218514349700_REF26","doi-asserted-by":"crossref","unstructured":"Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99: 754-758.","DOI":"10.1182\/blood.V99.3.754"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/10\/3982\/1697541\/zh801004003982.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/10\/3982\/1697541\/zh801004003982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:45:52Z","timestamp":1581554752000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/10\/3982\/17665\/Chimeric-CD19-antibody-mediates-cytotoxic-activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,15]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-05-1735","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,15]]}}}